| Hazard Information | Back Directory | [Uses]
Immunomodulator. | [in vivo]
Lenercept (Ro 45-2081) inhibits Sephadex-induced lung injury in the rat[1].
Lenercept (TNFR-IgG; 0.8-20 μg/mouse; i.v.; once) can prevent or significantly delay endotoxin-induced lethality in mice when given prior to or shortly after endotoxin challenge[2]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 1 and 3 mg/kg | | Administration: | Intraperitoneal injection, 1 h before administration of Sephadex for the 24 h study or 1 h before and at 24 and 48 h after Sephadex for the 72 h study | | Result: | Inhibited the neutrophilia at 24 h after Sephadex. At 72 h after Sephadex, significantly reduced the neutrophil influx into bronchoalveolar lavage fluid (BALF) but had no inhibitory effect on eosinophil number. |
| Animal Model: | 6- to 8-week-old female BALB/c mice, septic shock model[2] | | Dosage: | 0.8, 4 or 20 μg/mouse | | Administration: | IV, single dose | | Result: | Injection 0.5 h prior to Salmonella abortus-derived endotoxin (LD100 dose) administration prevented lethality at a dose of 20 μg per mouse and provided partial protection at lower doses. Injection of 10 μg per mouse provided significant protection 0.5 h before, 0.5 h after, or 1 h after endotoxin injection but little protection 2 h after endotoxin injection. |
|
|
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|